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Antiretroviral therapy (ART) suppresses HIV replication in most
individuals but cannot eradicate latently infected cells established
before ART was initiated. Thus, infection rebounds when treat-
ment is interrupted by reactivation of virus production from this
reservoir. Currently, one or a few latently infected resting memory
CD4 T cells are thought be the principal source of recrudescent
infection, but this estimate is based on peripheral blood rather
than lymphoid tissues (LTs), the principal sites of virus production
and persistence before initiating ART. We, therefore, examined
lymph node (LN) and gut-associated lymphoid tissue (GALT)
biopsies from fully suppressed subjects, interrupted therapy,
monitored plasma viral load (pVL), and repeated biopsies on 12
individuals as soon as pVL became detectable. Isolated HIV RNA-
positive (vRNA+) cells were detected by in situ hybridization in LTs
obtained before interruption in several patients. After interrup-
tion, multiple foci of vRNA+ cells were detected in 6 of 12 individ-
uals as soon as pVL was measureable and in some subjects, in
more than one anatomic site. Minimal estimates of the number
of rebounding/founder (R/F) variants were determined by single-
gene amplification and sequencing of viral RNA or DNA from pe-
ripheral blood mononuclear cells and plasma obtained at or just
before viral recrudescence. Sequence analysis revealed a large
number of R/F viruses representing recrudescent viremia from
multiple sources. Together, these findings are consistent with
the origins of recrudescent infection by reactivation from many
latently infected cells at multiple sites. The inferred large pool of
cells and sites to rekindle recrudescent infection highlights the
challenges in eradicating HIV.
HIV/AIDS | founder population | treatment interruption |
viral recrudescence
Antiretroviral therapy (ART) suppresses HIV-1 replication toundetectable levels in peripheral blood (PB) in most patients
but cannot cure infection, because infection is rekindled by reac-
tivation of virus production in latently infected memory CD4 T
cells when ART is discontinued for any reason (1–5). Subsequent
local expansion of infection and dissemination then reestablishes
a robust systemic infection in the absence of suppressive ART.
This reconstruction of events in recrudescent infection in many
ways recapitulates establishment of acute HIV-1 infection after
sexual mucosal exposure by a single transmitter/founder virus (6),
but the number of rebounding/founder (R/F) that emerges with
treatment interruption has not been determined. The parallels with
acute infection also suggest that the sources of rebounding virus in
PB are the lymphoid tissues (LTs), which are the principal sites for
virus production and persistence in HIV and simian immunodefi-
ciency virus infection (7–12), but these LT reservoirs in re-
crudescent infection also have not been characterized.
To that end, we sampled inguinal lymph node (LN) and gut-
associated lymphoid tissue (GALT) from HIV-infected subjects
with longstanding viral suppression on ART, interrupted treat-
ment, and then repeated LT sampling and reinstituted ART
immediately after detection of PB viremia. We also derived
minimal estimates of the number of R/F HIV variants in
recrudescent viremia by single-genome amplification and phy-
logenetic analyses first described for viral transmission and acute
infection (6). We show that recrudescent viremia is associated
with multifocal infection in LTs and the generation of multiple
R/F viruses in the PB. Thus, multifocal productive infection in
LT and reactivation of virus production in many latently infected
cells were sites and potential sources of rebound viremia in
a significant proportion of the patients who we studied. These
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findings underscore the challenges in eradicating such a large
reservoir to achieve a cure.
Results
Demographic Characteristics of the Cohort.We enrolled 14 subjects
into this University of Minnesota Institutional Review Board-
approved protocol, and 12 subjects completed the study. Base-
line characteristics of 14 study patients are shown in Table 1. All
subjects were male with a median age of 44 y (26–61 y). Median
durations of HIV infection and ART use were 14.6 y (3–25 y)
and 10.1 y (1–19 y), respectively. All had been virally suppressed
for at least 1 y before enrollment. One-half reported a history of
an AIDS diagnosis, with a median CD4 nadir of 264 cells/μL
(64–475 cells/μL). Two subjects reported an AIDS diagnosis
because of non-Hodgkin lymphoma and a history of Pneumo-
cystis jirovecii pneumonia, although their CD4 nadirs were
>300 cells/μL.
The 14 subjects were on multiple ART regimens. Four subjects
(1,670, 1,675, 1,775, and 1,791) were on efavirenz-containing
regimens, which were replaced by atazanavir and ritonavir 1 mo
before structured treatment interruption (STI) because of the
long half-life of efavirenz to reduce the probability of de-
velopment of resistance. Two subjects (1,825 and 1,906) were on
raltegravir-based regimens, and the remaining subjects were on
protease inhibitor-based regimens. All subjects had been on their
regimen for at least 1 y before study enrollment.
STI Experimental Design. We designed a short STI to assess LT
sources of recrudescent viremia, in which we obtained baseline
biopsies of LNs and GALT, interrupted treatment, and mea-
sured plasma viral load (pVL) at baseline and then on Monday,
Wednesday, and Friday during treatment interruption. When
virus became detectable (>75 copies/mL for the first five subjects
and >48 copies/mL for the remainder of the subjects), subjects
returned for repeat LT biopsies and were placed back on ther-
apy. pVL was then measured weekly until undetectable and then
every other week until two consecutive measures were un-
detectable. Study follow-up was then discontinued. The protocol
specified that if subjects did not develop detectable pVL within
21 d of stopping ART, biopsies were repeated, and their original
ART regimens were restarted. CD4 T-cell counts were obtained
at all time points that pVL was measured.
After discontinuation of ART, the median time to detectable
pVL was 14 d (range = 5–29 d) (Fig. 1 and Table 1). Two sub-
jects did not develop viremia by day 21. ART was restarted on
day 22 in one of the subjects (1,791). However, the other (1,775)
subject opted to stay off of therapy until the development of
viremia, which occurred at day 29. Biopsies were performed, and
ART was reinitiated a mean of 5 d after the detection of viremia
(range = 0–6 d). The delay of a few days to reinitiating ART
reflects the time needed for bowel preparation for the colonos-
copy and scheduling the LN biopsy. At the time that therapy was
restarted, the median pVL was 1,552 copies/mL (range was <48–
23,402 copies/mL), and the median time to undetectable pVL
was also 14 d (range = 6–47 d).
Three subjects had undetectable viremia within 7 d, and an
additional eight subjects had undetectable viremia by 3 wk. pVL
in the remaining two subjects was undetectable at days 40 and
47 after restarting ART. After viremia was undetectable, it
remained undetectable in all subjects for two consecutive bi-
weekly measures, at which time monitoring was discontinued.
The TRUGENE commercial genotype/phenotype resistance
assay was obtained on plasma from a time point immediately
after viremia was detected, and in all cases, there were no new
mutations detected that conferred resistance to any of the drugs
used. Reactivation of viral replication was not associated with
any clinical symptoms in any subject.
The median CD4 count at study entry was 561 cells/μL (range =
294–970 cells/μL), and at the time of viremia, it was 452 cells/μL
(range = 200–1,113 cells/μL). The median CD4 count at the last
visit (median of 41 d after treatment interruption; range = 19–
90 d) was 564 cells/μL (range = 216–924 cells/μL). There was no
significant change in CD4 T-cell count during the study (the
P value for a linear CD4 trend over time was 0.18) (Fig. 2).
Using an alternate analysis method, where we fit a model with
linear and quadratic changes over time, we detected a transient
decline in CD4 levels (P < 0.005) during the treatment in-
terruption, but levels returned to baseline after resumption of
ART. As we later comment, these rapid changes in CD4 T-cell
levels in PB could well represent CD4 T-cell redistribution (13,
Table 1. Demographic characteristics of the cohort and data on treatment interruption
Identification Age (y) Years HIV+* ART (y)
CD4 nadir
(cells/μL)
CD4 at entry
(cells/μL)
Days to viral
rebound
Peak viral load
(copies/mL)
Total days
off ART
Days to viral
suppression after
treatment
resumption
1064 61 25 17 89 307 15 6,663 20 14
1435 47 5.5 5.5 195 506 14 815 18 18
1670 37 18 11 390 672 14 7,895 19 47
1674 31 10 9.5 380 970 12 1,552 14 7
1675 26 5 1 343 294 19 1,833 24 7
1677 49 23 19 64 898 11 23,402 16 21
1775 49 12 12 475 857 29 60 29 8
1791† 55 24 13 464 663 NA NA 22 NA
1825 43 17 17 201 537 12 555 15 8
1837 46 11 10 109 492 9 308 10 40
1849 32 3.5 1.5 350 376 19 106 20 15
1853 47 23 15 200 420 14 857 20 20
1906 52 25 7 175 377 5 871 10 14
1928 43 3 3 270 492 16 1,820 22 6
Mean (range) 44.1 (26–61) 14.6 (3–25) 10.1 (1–19) 264.6 (64–475) 561 (294–970) 14.4 (5–29) 3,595 (60–23,402) 18.5 (10–29) 17.3 (6–47)
NA, not applicable.
*Years from first positive HIV test.
†Subject did not become viremic.
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14) without a significant impact on population levels in the LTs,
where they mainly reside (8, 15, 16).
Factors Affecting Time to Detection of Plasma HIV RNA. We exam-
ined variables that might predict time to the development of
viremia by assessing relationships between time to viremia, du-
ration of HIV infection, baseline CD4 count, years on ART,
CD4 nadir, and age. We found that the longer the duration of
HIV infection (i.e., the longer time since the positive HIV test)
and the shorter the duration of ART, the more quickly viremia
developed after treatment interruption (P = 0.019 and P = 0.029,
respectively). Similarly, lower reported CD4 nadir was associated
with more rapid development of viremia (P = 0.016). Baseline
CD4 count and age were not associated with time to viremia.
Time to viral suppression after interruption and resumption of
ART was not associated with age, duration of HIV infection,
baseline CD4, years on ART, or CD4 nadir. We also examined
changes in several inflammatory markers, including IL-6,
D-Dimer, TNF, intestinal fatty acid binding protein (I-FABP),
and soluble CD14 (sCD14), from baseline samples of plasma in
seven subjects and frequency of Ki67+ cells in LN in all subjects.
Pairwise associations using inflammatory marker data at the start
of the treatment interruption and at the time of viremia revealed
no significant association.
Detection of HIV RNA in LT.Before treatment interruption, we were
able to sample LN, ileum, and rectum biopsies from all subjects,
and repeat biopsies were performed in 12 of 14 subjects at the
time of recrudescence. Because of inherent limitations in the
biopsy procedure (unable to find LN or inadequate bowel
preparation), there was some variability in successfully sampling
all three sites in all subjects at the time of recrudescent viremia.
We were able to obtain LN, ileum, and rectum in 5 of 12 sub-
jects, LN and rectum in 4 of 12 subjects, ileum and rectum in 2 of
12 subjects, and only rectum in 1 of 12 subjects.
Using 35S-labeled HIV-specific riboprobes and in situ hy-
bridization (ISH) (17), we detected a single focus of HIV RNA-
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Fig. 1. Time to detectable plasma viremia and peak before restarting ART. The pVL from study entry (before treatment interruption) to restarting ART is
plotted against time for each subject. The difference in time between first detection and peak represents the time required for scheduling procedures and
completing the colonoscopy preparation.
Fig. 2. Change in PB CD4 T-cell count during and after the interruption. PB
CD4 T-cell count is plotted for each subject at baseline (while fully sup-
pressed), at the time when viremia is first detected, at the peak (the day of
biopsy), and again after the subject is fully suppressed. The black line indi-
cates the mean for the group at each time point. There is no statistically
significant change in CD4 T-cell count during the interruption or after pVL is
again suppressed (the P value for a linear CD4 trend over time was 0.18).
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positive (vRNA+) cells at very low density in LN obtained from
3 of 12 subjects (1,677, 1,825, and 1,928) before treatment in-
terruption (Table 2), a finding with an interpretation that we
later discuss vis à vis the recently documented lower anti-
retroviral (ARV) levels in LNs (17). At baseline, all GALT
samples (ileum and rectum) were negative. After treatment
interruption (Table 2), vRNA+ cells were detected in LT
obtained from 6 of 12 subjects (1,064, 1,675, 1,677, 1,825, 1,853,
and 1,906) and from 4 of 6 subjects (1,064, 1,825, 1,853, and
1,906) in multiple anatomic sites (Fig. 3 and Table 2). Virus
bound to the follicular dendritic network (FDCn) was also
detected in three of six subjects (1,064, 1,675, and 1,853), and
importantly, in subject 1,853, there was significant deposition of
virus on the FDCn when the pVL was <1,000 copies/mL (Table
2). We later discuss the implied duration of infection along with
the high density of vRNA+ cells in this subject relevant to uni-
focal vs. multifocal models of recrudescence (Fig. 5). At the time
of biopsy, the pVL, the time to viral recrudescence after treat-
ment interruption, and the time to biopsy after recrudescence
did not differ between subjects with detectable vRNA+ cells and
subjects in whom vRNA+ cells were not detected.
Sequence Analysis of R/F Virus. We used single-genome amplifi-
cation and direct sequencing of full-length env (gp160) to pro-
vide an unbiased assessment of the genetic diversity of R/F virus
obtained from vRNA in plasma and peripheral blood mono-
nuclear cells (PBMCs) and viral DNA (vDNA) from PBMCs.
Blood plasma and PBMCs for sequencing were obtained from
2 d before detectable viremia to 2 d after rebound viremia. We
obtained 311 single genome-amplified env sequences from 11
subjects with sufficient material for analysis. Phylogenetic anal-
ysis of all 11 subjects revealed individual clades for each patient,
with no interpatient mixing of sequences (Fig. S1). Three sub-
jects (1,928, 1,064, and 1,670) were excluded from intrapatient
analyses because of insufficient sequencing data for intrapatient
analyses. The remaining eight subjects had an average of 38 full
env sequences combining vRNA and vDNA sequences (range =
10–65). In several subjects, individual lineages with sequences
that were identical or nearly identical were observed, representing
Table 2. Frequency of detection of HIV by in situ hybridization in each anatomic compartment
LN Ileum Rectum
Identification
and time point vRNA+ cells* FDC† vRNA+ cells* FDC† vRNA+ cells* FDC† pVL
1,064
D0 0 0 0 <75
V NTO 2,870 33,300 + 6,662
1,435
D0 0 0 0 <48
V 0 NTO 0 815
1,670
D0 0 0 0 <75
V 0 0 0 7,895
1,674
D0 0 0 0 <75
V NTO NTO 0 1,552
1,675
D0 0 0 0 <75
V 2,680 + NTO 0 1,833
1,677
D0 79 0 0 <75
V 67,900 NTO NTO 23,042
1,775
D0 0 0 0 <48
V 0 0 0 60
1,791
D0 0 0 0 <48
V 0 0 0 <48
1,825
D0 626 0 0 <48
V 1,370 0 2,100 555
1,853
D0 0 0 0 <48
V 106,000 + 25,000 + 0 857
1,906
D0 0 0 0 <48
V 16,800 0 8,270 871
1,928
D0 643 0 0 <48
V 0 0 0 1,820
D0, day 0; FDC, follicular dendritic cell network accumulation of HIV; NTO, no tissue obtained; V, day HIV first
detected in peripheral blood.
*vRNA+ cells per 1 g tissue.
†Significant accumulation of HIV virions on the FDC network.
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reactivation of virus production from a single latently infected
cell or a clonally expanded population. However, the vast ma-
jority of sequences from all subjects represented unique viral
lineages with extensive genetic diversity (Fig. 4). The mean
intrapatient diversity was determined by pairwise analysis and
ranged from 0.7% to 5.3%. The maximum intrapatient diversity
was also determined by pairwise analysis and ranged from 2.2%
to 9.0%.
Discussion
One widely held view of the origins of recrudescent infection
when ARVs are discontinued is that infection begins by re-
capitulating the events in acute infection after a sexual trans-
mission. Here, a small founder population of infected cells is
established that then expands and seeds distal LT sites, where
additional expansion establishes systemic infection (6, 18). For
recrudescent infection, the initial event is reactivation of virus
production in a latently infected CD4 T cell, with similar sub-
sequent expansion and dissemination (Fig. 5).
This model is based on extensive studies of PB and therefore,
not informed by direct analysis of viral reservoirs and sources of
production in the LTs. Here, we report studies of the LTs during
a short STI, in which we detected evidence in a significant pro-
portion of subjects of multiple foci of vRNA+ cells in distinct LT
sites and in the majority of subjects, highly genetically diverse
viral populations in the PB. We interpret these findings as sup-
port for a multifocal model (Fig. 5) of recrudescent infection
rekindled by reactivation in many more latently infected memory
CD4+ T cells than has been appreciated in the past but con-
sistent with recent estimates of latently infected cells with
Fig. 3. HIV recrudescence from multiple anatomic sites on treatment interruption detected by ISH. A and B are of LN and ileum, respectively, obtained from
subject 1,853, a 47-y-old male infected for 23 y and on ART for 15 y. pVL at the time of recrudescence was 857 copies/mL. When viewed in epipolarized light,
the in situ hybridization signal for HIV RNA is a collection of green silver grains over cells or the FDCn (viral RNA in virions bound to the FDCn). (A) Arrow
points to a dense cloud of virus particles attached to the FDCn. C and D are of ileum and rectum, respectively, from subject 1,064, a 61-y-old male infected for
25 y and on ART for 17 y. pVL at the time of the biopsy was 6,663 copies/mL. E and F are from LN and rectum, respectively, from subject 1,906, a 52-y-old male
infected for 25 y and on ART for 7 y. pVL at the time of biopsy was 871 copies/mL.
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replication-competent proviruses in PB alone (19), the 20- to 60-fold
more CD4+ T cells that reside in LT compared with PB (8, 15,
16), and direct early estimates by in situ PCR of ∼1010 covertly
infected (vDNA+ vRNA−) helper CD4+ T cells in LT (7).
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Fig. 4. Phylogenetic analysis of PBMCs and plasma viruses at recrudescence. Intrapatient phylogenetic analysis of eight patients revealed multiple variants
initiating the reemergence of plasma viremia (blue). Additionally, PBMC-derived vRNA (orange) and vDNA (red) sequences revealed a highly divergent
population likely contributing to recrudescent viremia. Patient identification and scale bar (nucleotide substitutions per site) are provided with each maxi-
mum likelihood tree along with the percentage of bootstrap support for each node with values greater than 80%.
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Evidence of multifocal LT infection does not per se distinguish
between recrudescent infection originating in one, a few, or
many sites, because hypothetically, a local infection could seed
distal sites at levels of virus in PB below the limits of detection;
thus, the multifocal infections at the time that viremia was
detected could simply reflect virus production from this earlier
undetected spread (Fig. 5). However, there are some features of
the multifocal LT infection that are more consistent with in-
fection originating at multiple sites. Specifically, subjects 1,825,
1,853, and 1,906 had evidence of extensive LT infection and
FDC deposits, implying considerable duration of infection, but
pVLs were very low, suggesting that infection in LTs preceded
rather than followed recent dissemination to these sites.
The striking genetic diversity and complex phylogenetic trees,
with identification of 5–25 R/F viruses in the majority of subjects,
are, in our view, the most compelling evidence for the multifocal
origins of recrudescent infection. One subject did have viral
sequences composed of identical or nearly identical variants
(1,674), which could represent either recrudescent viremia from
a single viral source followed by viral expansion or a low-diversity
lineage originating from multiple sources that have clonally ex-
panded during therapy. The virus in these low-diversity clusters
might have begun replicating before the other clones or had
a fitness advantage to allow for an increase in the proportion.
Alternatively, viral rebound was initiated from multiple sources
that included clonally expanded virus that is genetically in-
distinguishable but outgrew other sources because of a larger
initial infected population. Both explanations are possible but
indistinguishable from this analysis. Similarly, Kearney et al. (20)
assessed viral sequences in PB in five subjects before treatment,
on therapy, and after treatment interruption and found that
rebounding virus primarily consisted of a population of identical
sequences. This result is consistent with a stable, nonevolving
reservoir as the source of rebound viremia. However, the results
are also consistent with recrudescent viremia from a single viral
source leading to systemic dissemination or from multiple sources
in LT that have clonally expanded before rebound. In this study,
we were limited to postinterruption samples and in some cases,
only PBMC samples for genetic analysis, but despite these limi-
tations, the complex and divergent viral population found imme-
diately after treatment interruption shows a very large underlying
reservoir population capable of reestablishing viremia.
This LT study was limited in the sampling possible in human
studies. To put this in perspective, we sampled 1 LN at each time
point of ∼500 LNs in the average human and detected vRNA+
cells in one-half of the subjects in sections representing 3 × 10−4%
of the LN tissue in a 75-kg individual. Similarly, for GALT
samples, the area of the intestine in a normal adult human is
∼300 m2, whereas the area of a pinch biopsy is 3 × 10−6 m2. We
analyzed a total of 28 pinch biopsies (i.e., 14 from ileum and 14
from rectum, which is 8.4 × 10−5 m2 tissue), which represents
∼2.8 × 10−5% of the total area of the intestine. Thus, the de-
tection of vRNA+ cells at multiple sites in so many patients is all
the more remarkable and consistent with reactivation at many
sites when treatment was discontinued.
In the context of the limited sampling of LT, the detection of
vRNA+ cells in LN biopsies of three subjects before dis-
continuing ARVs is also remarkable. In these in situ hybridiza-
tion snapshots of infection, vRNA+ cells could be examples of
transcriptional reactivation in latently infected cells or continu-
ing viral replication in LT viewed as a system. By this we mean
that, under suboptimal ARV drug levels in LN, there are, per-
haps, a few cycles of virus production and rounds of infection
at multiple sites in the LT system as a whole (unlike in vitro
infections, where ongoing replication will be detectable within
a confined system of infected cells and permissive target cells).
The smaller proportion of subjects and the fewer vRNA+ cells in
this cohort of well-suppressed subjects are also consistent with
our prior analysis of a cohort of patients at 6 mo after initiating
ARVs. In the work by Fletcher et al. (17), it was shown that the
rates at which the FDC pool and infected cells decayed slowed in
four of eight subjects, consistent with a low level of ongoing
replication. Detecting a low frequency of vRNA+ cells in LT of
long-term suppressed subjects is, thus, quite consistent with ex-
trapolating this slowed rate at 6 mo to this time frame.
Our findings also highlight several additional points regarding
HIV reservoirs. We found that time to viremia was more rapid in
subjects with low CD4 nadir, consistent with evidence that CD4
depletion is a strong predictor of viral reservoir size (21), and
subjects with longer duration of infection and a shorter period of
exposure to suppressive ART, suggesting, as has been reported,
that duration of viremia drives reservoir size (22–24). We also
found that the longest time to rebound viremia (29 d) was ob-
served in a subject who had been started on ART within 6 mo of
acquiring infection, consistent with reports that early treatment
limits reservoir size but does not prevent the recrudescence of
viremia in the absence of ART (25).
Given the focus on developing therapies aimed at producing
functional cure and the need to test the efficacy of such therapies
by interruption of standard ART, it is important to note that
our protocol was safe and well-tolerated by all participants. As
expected, the majority of subjects developed detectable viremia
during treatment interruption, but all achieved rapid viral sup-
pression after reinitiation of ART and remained virally sup-
pressed during follow-up. No resistance-conferring mutations
were detected in any subjects on viral rebound. Importantly, we
found no significant overall change in CD4 count associated with
our short STI. We detected a transitory decline in CD4 levels
shortly after treatment interruption, but counts then rebounded
Fig. 5. Model of the origins of recrudescent infection from one or many
cells and sites. The model is based on events in early infection after sexual
exposure (18) and the main types of infected cells in LT (8, 29, 30). When
infected cells are detected after STI in LT biopsies, they theoretically could
represent systemic infection seeded from a single focus or multiple foci, with
levels of virus in the blood below the limits of detection. However, in the
multifocal model, there is a greater likelihood of sampling a site from which
infection initiated. In this case, there will be many infected cells in the focus
and FDC deposits of virus, reflecting the greater duration of infection. The
most important distinction, however, is virus genetic diversity, which will be
greater in recrudescent infection from multiple cells and sites vs. mono-
phyletic viruses from a single reactivating focus.
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and returned to pre-STI levels over the remaining duration of
the protocol. This rapid decline and rebound are consistent with
previous observations on CD4 T-cell redistribution (13, 14) and
the conclusion that very short therapy interruptions in subjects
with preserved CD4 counts do not have the ongoing detrimental
immunologic impact seen with longer treatment interruptions.
The safety of brief STI is supported by several other studies (26–
28) showing that brief STIs do not affect overall CD4 T-cell
count and importantly, do not diminish immune function as de-
termined by antigen recall responses.
In summary, we show that virus rebound on treatment in-
terruption is evident at multiple sites with a highly complex and
genetically diverse population of virions, consistent with reac-
tivation from a large pool of latently infected cells. Efforts at
eradication will need to target these multiple reservoirs if a cure
strategy is to be successful.
Materials and Methods
Study Population. Between July of 2009 and April of 2011, in total, 14 subjects
were enrolled into this treatment interruption protocol. Subjects were required
to be virally suppressed on uninterrupted ART for at least 12 mo, have a CD4
count >350 cells/μL, have no history of prior treatment interruptions, have no
contraindications to study procedures, and have palpable inguinal LNs at
screening. All subjects provided written informed consent, and the study was
approved by the University of Minnesota Institutional Review Board.
Study Procedures. At screening, PB was obtained to determine CD4 count and
pVL, and physical examination was performed to ensure the presence of
palpable inguinal LNs. One month before study initiation, ART was adjusted
in patients taking a nonnucleoside reverse transcriptase inhibitor (NNRTI)-
based regimen to a protease inhibitor-based regimen given the long half-life
of NNRTIs and the risk of resistance in the setting of treatment interruption.
Usual nucleoside/nucleotide reverse transcriptase inhibitors and raltegravir
were continued.
At study initiation, subjects underwent bowel preparation using Go-
Lytely. The next day, blood was obtained for pVL, CD4 count, complete
blood count (CBC), comprehensive metabolic panel (CMP), and isolation of
plasma and mononuclear cells. Colonoscopy with 14 snip biopsies of both
the terminal ileum and rectum was performed followed by inguinal LN re-
section under local anesthesia. The subject was then instructed to stop ART.
After ART discontinuation, pVL and CD4 were monitored three times
weekly; pVL results were available within 24 h of blood draw. After pVL was
detectable, repeat biopsies were scheduled, and the subject underwent
bowel preparation the day prior. On the day of biopsies, blood was obtained
for pVL, CD4, CBC, CMP, genotype/phenotype, and isolation of plasma and
mononuclear cells for viral sequencing. Colonoscopy with biopsies and LN
resection were then repeated, and the subject’s usual ART regimen was
restarted. If subjects did not develop detectable virus within 21 d of ART
discontinuation, CBC, CMP, and CD4 were obtained, biopsies were re-
peated, and ART was restarted on day 22. After reinitiation of therapy, pVL
and CD4 count were obtained weekly until undetectable and then, every
other week until two consecutive measures were undetectable. In a subset
of subjects, plasma levels of IL-6, sCD14, and I-FABP were determined at
study initiation.
Clinical and Study Laboratory Procedures. HIV-1 viral load testing was per-
formed at the Hennepin County Medical Center Clinical Virology Laboratory.
Siemens assay platform with a limit of detection of 75 copies/mL was used for
subjects 1,064, 1,670, 1,674, 1,675, and 1,677. The Roche platform, with a limit
of detection of 48 copies/mL, was used for all other subjects. CD4 count, CBC,
and CMP testing were performed at the University of Minnesota Fairview
Clinical Laboratory. Siemens TRUGENE HIV-1 genotype/phenotype assay was
used to detect ART resistance.
For isolation of plasma, PB was collected in acid citrate dextran tubes.
Tubes were centrifuged at 400 × g for 10 min at room temperature. Plasma
was removed and stored at −80 °C until shipment to the National Institutes
of Health. For PB mononuclear cell isolation, blood collected in acid citrate
dextran tubes was diluted 1:1 with PBS. A matched volume of Histoplaque-
1077 was pipetted into an empty conical tube, and diluted blood was
overlaid. The tube was then centrifuged at 400 × g for 30 min at room
temperature without a brake. The buffy coat layer was then pipetted off
and divided between two 50-mL conical tubes. Complete RPMI (CRPMI)
was added to each tube to bring the total volume to 50 mL. Tubes were
centrifuged at 400 × g for 10 min at room temperature. Liquid was pipetted
off of the cellular pellet. Pellets were combined and resuspended in 25 mL
CRPMI; then, they were centrifuged at 250 × g for 10 min to remove plate-
lets. The pellet was resuspended in 20 mL CRPMI. A 10-μL aliquot was
removed and added to 90 μL trypan blue for counting by hemocytometer.
The cell suspension was centrifuged at 400 × g for 5 min at room temper-
ature. The cell pellet was then resuspended in Freezing Media [90% (vol/vol)
FBS:10% (vol/vol) DMSO] to achieve a concentration of 1 × 107 cells/mL.
Commercially available ELISAs were used according to the manufacturers’
protocols for measuring sCD14 (R&D Systems), IL-6, and I-FABP (Cell
Sciences).
In Situ Hybridization. At the time of collection, samples of LN, ileum, and
rectum were transferred directly to 4% (vol/vol) paraformaldehyde for 4–6 h,
washed in 80% (wt/vol) ethanol, and embedded in paraffin. Five-micrometer
sections were used for in situ hybridization. Five-micrometer-thick sections
from the paraffin-embedded tissue were cut through the entire tissue block.
We analyzed a total of 20 sections from each block using every fourth sec-
tion so that we were measuring virus production in 20-μm intervals. After
deparaffinization with xylene and rehydration through graded ethanols,
tissue sections were treated with HCl, triethanolamine, digitonin, and
4 μg/mL Proteinase K as described (17). After acetylation with acetic anhydride
and dehydration, they were hybridized at 45 °C overnight with a 35S-labeled
riboprobe and 0.5 mM aurintricarboxylic acid in the hybridization mix. After
extensive washes and ribonuclease treatment, tissue sections were dehy-
drated, coated in Ilford K5 emulsion diluted with glycerol and ammonium
acetate, exposed at 4 °C for 7–14 d, developed, and fixed per the manu-
facturer’s instructions. They were stained with hematoxylin, dehydrated, and
mounted with Permount. Photographic images using epifluorescence were
taken with a digital camera, and the tif images were analyzed for the area of
the sections and the area occupied by silver grains using Photoshop with Fovea
Pro. Section weights were estimated from their 5-μm thickness and area and
density of fixed tissues (9).
Single-Genome Amplification and Analysis. The HIV-1 env gene was amplified
from cell-associated vRNA or genomic DNA and from vRNA in blood plasma.
Cell-associated viral RNA is a good surrogate for replicating virus and was
used in conjunction with plasma viral RNA where samples were available.
Single-genome amplification followed by the direct sequencing approach
was used to eliminate Taq-induced errors and in vitro recombination as
described (6). Viral RNA and genomic DNA were isolated from PBMCs using
Phenol extraction, and vRNA was isolated from plasma using a QIAamp Viral
RNA Kit (Qiagen). Viral RNA was reverse-transcribed into cDNA in a final
volume of 100 μL, including 50 μL viral RNA, 5 μL dNTP mix (each at 10 mM),
1.25 μL antisense primer envB3out 5′-TTG CTA CTT GTG ATT GCT CCA TGT-3′
at 20 μM, 20 μL 5× first-strand buffer, 5 μL DTT at 100 mM, 5 μL RNaseOUT
(Invitrogen), and 5 μL SuperScript III reverse transcriptase. RNA, primers, and
dNTPs were heated at 65 °C for 5 min and then chilled on ice for 1 min; then,
the entire reaction was incubated at 50 °C for 60 min followed by 55 °C for
an additional 60 min. Finally, the reaction was heat-inactivated at 70 °C for
15 min and then treated with 1 μL RNase H each at 37 °C for 20 min. Then,
cDNA or DNA templates were serially diluted until only a fraction (∼25%) of
amplicons were PCR-positive with the following PCR conditions. PCR am-
plification was carried out using the Platinum Taq (Invitrogen) with 1×
buffer, 2 mMMgCl2, 0.2 mMeach dNTP, 0.2 μMeach primer, and 0.025 units/μL
Platinum Taq polymerase. The primers for the first-round PCR were envB5out
5′-TAG AGC CCT GGA AGC ATC CAG GAAG-3′ and envB3out 5′-TTG CTA CTT
GTG ATT GCT CCA TGT-3′. The primers for the second-round PCR were
envB5in 5′-CAC CTT AGG CAT CTC CTA TGG CAG GAA GAAG-3′ and envB3in
5′-GTC TCG AGA TAC TGC TCC CAC CC-3′. The cycler parameters were 94 °C
for 2 min followed by 35 cycles of 94 °C for 15 s, 55 °C for 30 s, and 68 °C for
4 min and a final extension of 68 °C for 10 min. The product of the first-
round PCR (1 μL) was subsequently used as a template in the second-round
PCR under the same conditions but with a total of 45 cycles. All PCR-positive
amplicons were directly sequenced using BigDye Terminator chemistry
(Applied Biosystems). Any sequence with evidence of double peaks was
excluded from additional analysis. Apolipoprotein B mRNA editing enzyme,
catalytic polypeptide-like mutated sequences, as determined by HyperMut
(www.hiv.lanl.gov), were retained in phylogenetic trees but excluded from
diversity analyses. Env sequences were aligned with ClustalW, and phylo-
genetic trees were constructed using maximum likelihood methods with
a general time reversible with γ-model implemented in MEGA-6 Mac. Di-
versity measurements were determined using pairwise comparisons. Ac-
cumulated changes within defined genetic clusters were characterized
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using Poisson fitter (www.hiv.lanl.gov). All 311 sequences were deposited
in GenBank with accession numbers KM081846–KM082156.
Statistical Methods. To test for a change in CD4 counts on initiating an STI,
a mixed effects model was used to account for the longitudinal nature of
these data, because most subjects had CD4 counts available every 2–3 d. The
model used the logarithm of the CD4 count as a response variable, with
time as the other response variable. Random intercepts were used to ac-
count for the within-subject correlation of measurements (models with
random slopes were also considered but provided a worse fit given the
increase in the number of parameters as judged by Akaike’s information
criterion). Restricted maximum likelihood was used to obtain parameter
estimates, and the test for no change over time was conducted using
a Wald test for the estimated slope over time. Linear and quadratic tem-
poral trends were considered in these models, and a likelihood ratio test
was used to test the fit of the model with quadratic effects over time to the
null model with no effect for time.
To test for associations between clinical variables and time to viremia,
a multiple linear regression model was fit that had the logarithm of the time
to viremia as the response variable and all variables from Table 1 that were
observed before initiating the treatment interruption (i.e., age, years posi-
tive, day 0 CD4 levels, years on treatment, and nadir CD4 count). Data from
the one subject who did not return to being viremic were excluded from
these models. Tests of the regression coefficients in these models were used
to test for associations between variables given the effect of other variables
in the model (i.e., we did not engage in any model-building exercise that
may result in overfitting). To investigate the robustness of the findings, we
also fit the same model but used a Cox proportional hazards model (which
allows inclusion of the data from the subject who did not become viremic).
Because of the small sample size, permutations were used to compute
P values. This analysis also detected significant associations between years
positive (P = 0.05) and nadir CD4 counts (P = 0.004), but the effect of years
on treatment just missed significance (P = 0.07). These slightly different
results are consistent with the lower power that one expects from a semi-
parametric model. All calculations were conducted using R, version 3.1.0 and
the lme and survival packages for R.
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Fig. S1. Unrooted phylogenetic tree of full-length gp160 shows no interpatient contamination. All 311 env sequences from 11 subjects are displayed, with
each subject’s sequences color-coded. All sequences from each subject cluster independently of all other subjects, representing a star-like phylogeny and
independent viral evolution within each subject.
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